The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 172)
Research Grant, 2018
As wearable technology -- smartphones and wearable devices with built-in sensors -- became increasingly more common, affordable and effective, its use in the evaluation and treatment of Parkinson's disease (PD) has advanced rapidly. Such technology can collect data on mobility, symptom intensity and medication effects. While useful, these devices have limitations: They must be wor...
Researchers: Dina Katabi, PhD, MS, BS
Target Advancement Program, 2018
The two main types of the enzyme 5α-reductase (5αR) play a key role in the production of steroids in the brain and other organs. In pre-clinical testing, we found that inhibitors of both major types of this enzyme prevent damage to brain cells that occur in Parkinson's disease and reduce the severity of dyskinesias. Dyskinesias are one of the major complications of standard treatm...
Researchers: Marco Bortolato, MD, PhD
Therapeutic Pipeline Program, 2018
Levodopa-induced dyskinesia is abnormal involuntary movements that can affect people with Parkinson's disease after years of treatment. Available therapies for dyskinesia are only partly effective to alleviate the abnormal movements, and dyskinesia remains a hindrance to quality of life. Several experimental treatments for dyskinesia have focussed on a chemical substance of the bra...
Researchers: Philippe Huot, MD, PhD
Research Grant, 2018
Cell replacement using induced pluripotent stem cells (iPSCs) is a potential restorative therapy for Parkinson's disease. Replacing brain cells that produce dopamine, a chemical affected in Parkinson's, could address both motor symptoms, as well as L-dopa-induced dyskinesias. The team, with previous MJFF funding, has completed pre-clinical dose-escalation studies demonstrating lon...
Research Grant, 2017
Promising Outcomes of Original Grant:
In our original proposal, we identified two chemical scaffolds (protein support structures) as dopamine receptor 4 (D4R) antagonists (compounds that block the activity of dopamine) and optimized their strength and ability to pass into the brain. We then tested the lead molecule in a pre-clinical model of L-DOPA-induced dyskinesias (LIDs), disabling involuntary ...
Researchers: Corey R. Hopkins, PhD